" class="no-js "lang="en-US"> Daiichi Sankyo Archives - Medtech Alert
Monday, June 17, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

Daiichi Sankyo has announced that the United States Food and Drug Administration (FDA) has extended […]

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today […]

ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo has announced that the European Medicines Agency (EMA) has validated the Type II […]

Enhertu Approved in the US for Patients with HER2-positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-based Regimen

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]

Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens

The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more